Clinical Trials
11 trialsNCT04693468 2026-03-13
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT01744652 2023-06-07
Dasatinib and Crizotinib in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02270034 2022-03-10
Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma
Grupo Español de Investigación en Neurooncología
Phase 1 Completed
NCT02207504 2022-01-06
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01548144 2021-09-13
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed
NCT01531361 2021-01-22
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01579994 2020-12-30
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01644773 2019-03-22
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01998126 2018-04-02
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
University of Utah
Phase 1 Completed
NCT02074878 2017-08-09
CRIZENT
Baylor Breast Care Center
Phase 1 Terminated